Rhythm Pharmaceuticals, Inc. (RYTM), a Boston-based commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, carries a near-unanimously bullish sell-side view. For this analysis, the central target is derived from the seven most recent, individually attributed analyst targets published after the company's third-quarter report in early November 2026. Those targets are: Canaccord Genuity's Whitney Ijem at $168, Citizens' Jonathan Wolleben at $166, Wells Fargo at $155, Guggenheim's Seamus Fernandez at $147, Morgan Stanley's Michael Ulz at $146, Citi's Samantha Semenkow at $143, and JPMorgan's Priyanka Grover at $142.
These seven range from $142 to $168 and average approximately $152, which rounds to a $150 central target. For context, independent aggregators that fold in targets not recently revised report a lower consensus near $140 (S&P Global, 19 analysts, range $112 to $168; FactSet, 18 analysts, near $142). The wide spread reflects genuine disagreement: some analysts weight the near-term commercial ramp of the lead drug, while others discount further out for pipeline and cash-burn uncertainty. The $150 figure here is a calculated mean, not an official published consensus.
Shares recently traded near $114, giving Rhythm a market capitalization of roughly $7.9 billion. Reaching $150 would require a gain of about 32% from current levels — a substantial move that would push the stock decisively through its 52-week high of $122.20. The path depends heavily on execution rather than valuation expansion: the company is not yet profitable on a GAAP (generally accepted accounting principles) basis, so investors are paying for future growth of IMCIVREE and the broader melanocortin-4 receptor (MC4R) franchise.
Trailing-twelve-month revenue is about $281 million, and the business has been growing quickly as IMCIVREE (setmelanotide) expands into acquired hypothalamic obesity and additional geographies. Sequential product sales rose roughly 19% in the most recent quarter, supporting the view that commercial traction is broadening beyond initial prescriptions into recurring reimbursed demand.
The stock's 52-week range spans $74.50 to $122.20. The $122 area marks a key resistance zone and prior high that would need to be cleared for any move toward $150. On the downside, recent trading established support in the $103–$105 zone, with a secondary shelf near the $112–$115 region. A decisive breakout above $122, ideally on volume, would be a meaningful technical confirmation, while a slide below $103 could signal renewed selling pressure.
Most analyst price targets reflect a roughly 12-month research horizon, though individual methodologies differ. Upcoming items most relevant to the target include quarterly earnings and guidance, IMCIVREE prescription and reimbursement trends, updates on RM-718 tolerability and development, and progress on international launches. Regulatory decisions, payer coverage changes, and any financing announcements also matter given the company's cash-burn profile. Investors should watch for analyst target revisions as a signal of shifting sentiment rather than as a forecast of a specific price.
AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help traders surface opportunities, track positions, and identify shifting trends more efficiently than manual screening. Investors interested in a systematic, data-driven layer on top of traditional research may want to explore these signals for RYTM and other names.
The question of whether RYTM can reach $150 hinges on sustained commercial execution rather than a single catalyst. The target, an average of seven recent analyst views spanning $142 to $168, sits about 32% above the current price and above the broader ~$140 consensus that includes older targets. Support comes from accelerating IMCIVREE revenue, label and geographic expansion, and encouraging RM-718 data. The principal obstacles are ongoing losses, cash-burn and dilution risk, slow patient diagnosis, and RM-718 tolerability. Because the stock is unprofitable, its value rests on growth expectations that can shift quickly with each earnings report and pipeline update. No outcome is guaranteed, and the wide target range underscores genuine disagreement about how quickly the rare-obesity opportunity converts into durable profits.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with SRRK. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then SRRK could also see price increases.
| Ticker / NAME | Correlation To RYTM | 1D Price Change % | ||
|---|---|---|---|---|
| RYTM | 100% | +8.49% | ||
| SRRK - RYTM | 51% Loosely correlated | +1.21% | ||
| GERN - RYTM | 45% Loosely correlated | +6.17% | ||
| COGT - RYTM | 45% Loosely correlated | +1.49% | ||
| XNCR - RYTM | 43% Loosely correlated | -2.54% | ||
| VIR - RYTM | 43% Loosely correlated | -3.44% | ||
More | ||||